Halozyme Therapeutics, Inc.
HALOCIK 0001159036 · last filing Jul 2, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
10,000 bought / 7,033 sold
net +2,967 sh · −$547.9K
- buys
- 1
- sells
- 3
- insiders active
- 2
Filing tape
Filed Thu, Jul 2, 2026
- +4,592 sh · $423.3K
Ramsay David A — EVP, PRESIDENT, DRUG DELIVERY
- Exercised10,000Common Stock→ 10,000 held
- Withheld for tax5,408Common Stock@ $78.27→ 4,592 held
- Exercised10,000Restricted Stock Units→ 0 held
- Granted16,232Restricted Stock Units→ 16,232 held
- Granted39,823Option to Purchase Common Stock→ 39,823 held
- ±0
Snellgrove Darren — SVP, Chief Financial Officer
- Granted41,554Restricted Stock Units→ 41,554 held
- Granted127,432Option to Purchase Common Stock→ 127,432 held
- −1,625 sh · $124.7K
Connaughton Bernadette — Director
- Sold1,000Common Stock@ $76.40→ 42,669 held
- Sold625Common Stock@ $77.21→ 42,044 held
Insiders on this tape
- Ramsay David AEVP, PRESIDENT, DRUG DELIVERY
- Snellgrove DarrenSVP, Chief Financial Officer
- Connaughton BernadetteDirector
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.